AM Investment Strategies LLC Has $3.07 Million Stake in Johnson & Johnson (NYSE:JNJ)

AM Investment Strategies LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 3.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,969 shares of the company’s stock after selling 729 shares during the period. Johnson & Johnson makes up about 0.7% of AM Investment Strategies LLC’s portfolio, making the stock its 22nd biggest holding. AM Investment Strategies LLC’s holdings in Johnson & Johnson were worth $3,074,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently modified their holdings of the stock. Pachira Investments Inc. boosted its holdings in shares of Johnson & Johnson by 6.4% in the 1st quarter. Pachira Investments Inc. now owns 4,353 shares of the company’s stock valued at $689,000 after purchasing an additional 262 shares in the last quarter. Massachusetts Wealth Management grew its position in Johnson & Johnson by 1.4% in the first quarter. Massachusetts Wealth Management now owns 17,572 shares of the company’s stock valued at $2,780,000 after acquiring an additional 250 shares during the last quarter. Kovack Advisors Inc. raised its stake in Johnson & Johnson by 9.4% during the first quarter. Kovack Advisors Inc. now owns 32,041 shares of the company’s stock worth $5,069,000 after acquiring an additional 2,759 shares in the last quarter. Cornerstone Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 5.0% in the first quarter. Cornerstone Wealth Management LLC now owns 42,109 shares of the company’s stock worth $6,661,000 after acquiring an additional 2,007 shares during the last quarter. Finally, First Trust Direct Indexing L.P. boosted its stake in shares of Johnson & Johnson by 10.5% in the 1st quarter. First Trust Direct Indexing L.P. now owns 55,544 shares of the company’s stock valued at $8,787,000 after purchasing an additional 5,298 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $160.13 on Friday. The stock has a market capitalization of $385.53 billion, a P/E ratio of 23.17, a price-to-earnings-growth ratio of 2.84 and a beta of 0.52. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm’s fifty day simple moving average is $163.31 and its two-hundred day simple moving average is $155.51. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the business earned $2.66 EPS. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.10%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

JNJ has been the subject of several research reports. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. TD Cowen reduced their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Royal Bank of Canada lifted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Finally, Morgan Stanley upped their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.